Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338144 | 0.90 | MME (0.42) | MMETAS1R3TAS1R1ALDH1A1PLA2G10 | |
| SCHEMBL14902238 | 0.85 | MGAM (0.35) | CNR1TDP1 | |
| SCHEMBL10902941 | 0.82 | ALDH1A1 (0.49) | MMETAS1R3TAS1R1ALDH1A1PLA2G10 | |
| SCHEMBL10902934 | 0.82 | ALDH1A1 (0.49) | MMETAS1R3TAS1R1ALDH1A1PLA2G10 | |
| SCHEMBL11073459 | 0.81 | ALDH1A1 (0.52) | MMETAS1R3TAS1R1ALDH1A1CNR1 | |
| SCHEMBL14294441 | 0.81 | ALDH1A1 (0.52) | MMETAS1R3TAS1R1ALDH1A1CNR1 | |
| SCHEMBL2417291 | 0.79 | TDP1 (0.43) | ALDH1A1CNR1TDP1 | |
| SCHEMBL4341862 | 0.79 | TAS1R3 (0.42) | MMETAS1R3TAS1R1ALDH1A1CNR1 | |
| SCHEMBL27105837 | 0.78 | PLA2G10 (0.47) | MMETAS1R3TAS1R1ALDH1A1PLA2G10 | |
| SCHEMBL21609362 | 0.78 | PLA2G10 (0.51) | MMETAS1R3TAS1R1PLA2G10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-9943498-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2018-04-17 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-9394324-B2 | Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | VIFOR (INTERNATIONAL) AG (CH) | 2016-07-19 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | VIFOR (INTERNATIONAL) AG (CH) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109662-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | MME 2565/4885TAS1R3 2683/4885TAS1R1 3766/4885 |
| US-20160310459-A1 | Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias | FECH, SDHB, SLC40A1 | MME 2565/4885TAS1R3 2683/4885TAS1R1 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.